NanoString Technologies, Inc.   Report issue

For profit Phase 2
Founded: Seattle WA United States (2003)

Organization Overview

First Clinical Trial
2015
NCT02400567
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

NanoString Technologies, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 9